Episode 218: Statin Therapy Fundamentals

Episode 218: Statin Therapy Fundamentals

Author: Rio Bravo Family Medicine Residency Program April 6, 2026 Duration: 17:12

Episode 218: Statin Therapy Fundamentals

What are statins?

Zohal: Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which prevents cholesterol synthesis in the liver. By doing so, statins decrease low-density lipoprotein cholesterol (LDL-C). 

Why should we lower LDL?

Zohal: There are four main lipoproteins that transport fats in blood, including chylomicrons, VLDL, LDL, and HDL. This is where we get our “bad cholesterol” vs. “good cholesterol”. Of these, LDL is most associated with an increased risk in cardiovascular disease, while a higher HDL is associated with lower risk. Thus, reducing LDL subsequently reduces the risk of cardiovascular disease. 

Arreaza: The lowest LDL I’ve seen was 25, and the highest HDL was 60. HDL doesn’t really have a strict upper limit, but most people fall between 40 and 60. Extremely high HDL—above 100—may not always be protective and can sometimes signal underlying issues.

Zohal: My HDL is 70! Statins are used for both primary prevention, meaning preventing cardiovascular disease before it occurs, and secondary prevention, meaning preventing disease progression in patients who already have cardiovascular disease.

History of statins.

Zohal: In the early 1900’s, researchers were studying the association between cholesterol and atherosclerosis, and at that time, they primarily used animal subjects. These studies were initially not taken seriously, because most believed cardiovascular disease in humans were simply due to aging and was not preventable. 

It wasn’t until the middle of the century when researchers began observing that increased levels of LDL and decreased HDL was correlated with an increased rate of heart attacks. This finding prompted interest in determining the pathway of cholesterol synthesis in the human body. 

Statins were first discovered in the 1970s when researchers identified compounds that inhibit a critical step in cholesterol synthesis. The first statin approved for clinical use was Lovastatin in 1987.

Since then, multiple statins have been developed, including Atorvastatin, Rosuvastatin, Simvastatin, and Pravastatin. Further clinical trials in the 1990s and 2000s showed that statins significantly reduce myocardial infarction, stroke, and cardiovascular mortality.

Why do Statins Matter in Primary Prevention

Zohal: Cardiovascular disease is the most common cause of death worldwide. As previously mentioned, elevated LDL cholesterol contributes to the development of atherosclerotic plaques within arteries, which can lead to heart attack and stroke. By lowering LDL cholesterol and stabilizing plaque formation, statins implemented in a timely manner significantly reduce the risk of atherosclerotic cardiovascular disease.

Arreaza: One of the things I love most about primary care is prevention. You’re working upstream, often quietly, humbly, helping people avoid disease before it starts. And the truth is—you rarely see the full impact of your actions. You don’t get a notification that says, “this patient didn’t have a heart attack because of you.” But every time you help someone control their blood pressure, quit smoking, improve their diet, or stay consistent with their medications, you’re shifting their tracks. You’re reducing risk in ways that may never be fully visible. That’s the paradox and the beauty of it: in primary care, your highest victories are often events that never happen. 

Who Should Receive Statins for Primary Prevention?

Zohal: Recommendations slightly differ depending on who you ask. We look to the U.S. Preventive Services Task Force, the American College of Cardiology, and the American Heart Association for their recommendations regarding statins for primary prevention.

USPSTF on statins.

The U.S. Preventive Services Task Force (or USPSTF for short) is an organization that works to improve the health of people nationwide by making evidence-based recommendations on effective ways to prevent disease & prolong life. They recommend statins for the primary prevention of cardiovascular disease in:

  • Adults 40–75 years old
  • With one or more cardiovascular risk factors such as dyslipidemia, diabetes, hypertension, or smoking
  • AND a 10-year cardiovascular risk of 10% or greater

Their recommendations are graded A, B, C, D, and I, depending on the strength of evidence and this is a Grade B recommendation.

Arreaza: So, you have to meet all the criteria to receive a statin, according to USPSTF: 40-75, one CV risk factor and a high 10-y ASCVD score, by the way, the ASCVD risk calculator was introduced in 2013 by AHA/ACC. It is available online for free and many EHRs have integrated this tool into their software. For example, if you use EPIC, you can type .ascvd and get a score automatically. What about patients with a cardiovascular risk less than 10%?

Zohal: For patients with a 7.5–10% risk, some may offer statin therapy on a case-by-case basis as this is a Grade C recommendation. But I’ll get more into this later.

Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! 

_____________________

References:

  1. Grundy SM, et.al, Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Erratum in: Circulation. 2019 Jun 18;139(25):e1182-e1186. doi: 10.1161/CIR.0000000000000698. Erratum in: Circulation. 2023 Aug 15;148(7):e5. doi: 10.1161/CIR.0000000000001172. PMID: 30586774; PMCID: PMC7403606. https://pubmed.ncbi.nlm.nih.gov/30586774/
  2. U.S. Preventive Services Task Force. (2022, August 23). Statin use for the primary prevention of cardiovascular disease in adults: Preventive medication.
    https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medicatio
  3. American College of Cardiology ASCVD Risk Estimator: https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/
  4. Guideline Central. (2026, March). ACC/AHA dyslipidemia guideline spotlight (March 2026).
    https://www.guidelinecentral.com/insights/mar-2026-accaha-dyslipidemia-guideline-spotlight/
  5. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-93. doi: 10.2183/pjab.86.484. PMID: 20467214; PMCID: PMC3108295. https://pubmed.ncbi.nlm.nih.gov/20467214/
  6. Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Tune into Rio Bravo qWeek for a genuine look inside the daily life and learning of a family medicine residency. Produced by the Rio Bravo Family Medicine Residency Program, this podcast brings you the voices of the residents and faculty themselves as they navigate the vast world of primary care. Each episode focuses on key medical topics and relevant clinical discussions, drawn directly from their training and experiences. What sets this series apart is its authentic tone-conversations here are often lightened with medical humor and peppered with practical Spanish medical terminology, reflecting the real-world needs of a diverse patient population. It’s a unique blend of solid education and relatable shop talk, offering insights for medical students, healthcare professionals, or anyone curious about the human side of medicine. You’ll find this podcast to be more than a lecture; it’s a window into the collaborative and ever-evolving journey of becoming a family physician.
Author: Language: English Episodes: 218

Rio Bravo qWeek
Podcast Episodes
Episode 157: Urine Testing [not-audio_url] [/not-audio_url]

Duration: 10:36
Episode 157: Urine TestingThis episode includes the pitfalls of urine tests, how to detect adulterated urine, and more. Written by Janelli Mendoza, MSIV, Ross University School of Medicine. Editing by Hector Arreaza, MD.…
Episode 156: Obesity, Fertility, and Pregnancy [not-audio_url] [/not-audio_url]

Duration: 18:00
Episode 156: Obesity, Fertility, and PregnancyFuture Dr. Hamilton defines obesity and explains the pathophysiology of obesity and its effects on fertility and pregnancy. Dr. Arreaza adds some input about the impact of ep…
Episode 155: Diabetic Foot Infection Guidelines [not-audio_url] [/not-audio_url]

Duration: 23:30
Episode 155: Diabetic Foot Infection GuidelinesFuture Dr. Perez presents the updates on lung cancer screening by the American Cancer Society. Future Dr. Danusantoso explains the classification, diagnosis, and treatment o…
Episode 154: Heart Failure and GDMT [not-audio_url] [/not-audio_url]

Duration: 17:57
Episode 154: Heart Failure and GDMTDr. Malave explains the four main medications that are part of the guideline-directed medical therapy of heart failure with reduced ejection fraction. Dr. Arreaza added comments and que…
Episode 153: Sudden Infant Death Syndrome [not-audio_url] [/not-audio_url]

Duration: 24:17
Episode 153: Sudden Infant Death Syndrome. Future doctors Nisha and Afolabi explain the way to prevent sudden infant death syndrome and Dr. Arreaza adds comments about prevention through vaccines. Written by Selena Nisha…
Episode 152: ALS Fundamentals [not-audio_url] [/not-audio_url]

Duration: 23:28
Episode 152: ALS FundamentalsFuture Dr. Rodriguez explains the symptoms of ALS, including UMN and LMN symptoms. Dr. Arreaza discusses the principles of symptomatic treatment by primary care. This is a brief introduction…
Episode 151: Martian Medicine 102 [not-audio_url] [/not-audio_url]

Duration: 17:01
Episode 151: Martian Medicine 102Future Dr. Collins discussed with Dr. Arreaza two common complications of astronauts in a hypothetical travel to Mars: Spaceflight-Associated Neuro-ocular Syndrome and mental illness. Wri…
Episode 150: Re-update on COVID Vaccines and Cervical Cancer [not-audio_url] [/not-audio_url]

Duration: 29:46
Episode 150: Re-update on COVID Vaccines and Cervical CancerCOVID vaccines have been updated (again). The bivalent m-RNA COVID-19 vaccines are no longer authorized in the US. Sabrina explains that the monovalent COVID-19…
Episode 149: COVID Vaccines (as of 9/10/23) [not-audio_url] [/not-audio_url]

Duration: 11:53
Episode 149: COVID Vaccines Update [Historic episode]. Future Dr. Williams presented an update on COVID-19 vaccines. This update is only for immunocompetent individuals, and it was recorded on August 24, 2023. Dr. Arreaz…
Episode 148: Leg Cramps [not-audio_url] [/not-audio_url]

Duration: 20:53
Episode 148: Leg CrampsFuture Dr. Weller explains the pathophysiology, management, and prevention of leg cramps. Hector Arreaza adds comments and anecdotes about leg cramps. Written by Olivia Weller, MS4, American Univer…